These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8672021)

  • 1. Increased serum concentrations of pro-gastrin-releasing peptide in patients with renal dysfunction.
    Kamata K; Uchida M; Takeuchi Y; Takahashi E; Sato N; Miyake Y; Okubo M; Kodama T; Yamaguchi K
    Nephrol Dial Transplant; 1996 Jul; 11(7):1267-70. PubMed ID: 8672021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pro-gastrin-releasing peptide (Pro-GRP), a tumor marker for small cell lung cancer.
    Oremek GM; Sapoutzis N
    Anticancer Res; 2003; 23(2A):895-8. PubMed ID: 12820319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer.
    Okusaka T; Eguchi K; Kasai T; Kurata T; Yamamoto N; Ohe Y; Tamura T; Shinkai T; Saijo N
    Clin Cancer Res; 1997 Jan; 3(1):123-7. PubMed ID: 9815547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma.
    Miyake Y; Kodama T; Yamaguchi K
    Cancer Res; 1994 Apr; 54(8):2136-40. PubMed ID: 8174119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
    Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
    Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of ProGRP31-98 in patients with small-cell lung cancer].
    Yang J; Li R; Li A
    Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):216-8. PubMed ID: 11778234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro-gastrin-releasing peptide as a factor predicting the incidence of brain metastasis in patients with small cell lung carcinoma with limited disease receiving prophylactic cranial irradiation.
    Yonemori K; Sumi M; Fujimoto N; Ito Y; Imai A; Kagami Y; Ikeda H
    Cancer; 2005 Aug; 104(4):811-6. PubMed ID: 15973666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlation between the tumor marker Pro-GRP and prognosis in patients with small-cell lung cancer].
    Tsuchiyama T; Kawahara M; Naka N; Yamamoto S; Nakao M; Kamimori T; Okada T; Atagi S; Ogawara M; Furuse K
    Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Jun; 35(6):616-21. PubMed ID: 9294294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
    Schneider J; Philipp M; Salewski L; Velcovsky HG
    Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
    Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
    Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of circulating adhesion molecules ICAM-1, VCAM-1 and E-selectin in Wegener's granulomatosis, systemic lupus erythematosus and chronic renal failure.
    Mrowka C; Sieberth HG
    Clin Nephrol; 1995 May; 43(5):288-96. PubMed ID: 7543387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis.
    David S; Kümpers P; Seidler V; Biertz F; Haller H; Fliser D
    Nephrol Dial Transplant; 2008 Apr; 23(4):1370-7. PubMed ID: 18089624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High levels of the proNGF peptides LIP1 and LIP2 in the serum and synovial fluid of rheumatoid arthritis patients: evidence for two new cytokines.
    Dicou E
    J Neuroimmunol; 2008 Feb; 194(1-2):143-6. PubMed ID: 18162190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoreactive gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma.
    Maruno K; Yamaguchi K; Abe K; Suzuki M; Saijo N; Mishima Y; Yanaihara N; Shimosato Y
    Cancer Res; 1989 Feb; 49(3):629-32. PubMed ID: 2535962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
    Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
    Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation--are they inter-related?
    Sebeková K; Podracká L; Heidland A; Schinzel R
    Clin Nephrol; 2001 Dec; 56(6):S21-6. PubMed ID: 11770807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.